Filtered By:
Specialty: Cardiology
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 478 results found since Jan 2013.

Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation
Conclusion In this prospective observational study, anticoagulation with NOACs following AF catheter ablation was safe and effective at long-term follow-up. Fast onset of action makes NOACs especially attractive in patients without effective anticoagulation on admission and in patients following periprocedural complications.
Source: Europace - October 29, 2013 Category: Cardiology Authors: Eitel, C., Koch, J., Sommer, P., John, S., Kircher, S., Bollmann, A., Arya, A., Piorkowski, C., Hindricks, G. Tags: Ablation for atrial fibrillation Source Type: research

Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Health Services and Outcomes Research
Conclusions Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding. Patients appeared to drive switching from warfarin, whereas clinical characteristics influenced de novo start of dabigatran. These data suggest cautious early uptake of dabigatran, and more careful attention to dosing adjustments is warranted. Clinical Trial Registration URL: Clinicaltrials.gov. Unique identifier: NCT01165710.
Source: JAHA:Journal of the American Heart Association - November 25, 2013 Category: Cardiology Authors: Steinberg, B. A., Holmes, D. N., Piccini, J. P., Ansell, J., Chang, P., Fonarow, G. C., Gersh, B., Mahaffey, K. W., Kowey, P. R., Ezekowitz, M. D., Singer, D. E., Thomas, L., Peterson, E. D., Hylek, E. M., The Outcomes Registry for Better Informed Treatme Tags: Health Services and Outcomes Research Source Type: research

There is a need for independent studies about new oral anticoagulants in atrial fibrillation patients
Dabigatran, rivaroxaban, and apixaban are new oral anticoagulants (NOAC) which have been investigated in patients with atrial fibrillation (AF) for primary and secondary prevention of stroke and thromboembolism . In RELY, ROCKET-AF and ARISTOTLE, NOAC had a similar efficacy and safety profile like vitamin-K-antagonists (VKA). Based on these results, NOAC are recommended by national and international societies as an alternative to VKA or even the first choice drug for the prevention of stroke or embolism in AF-patients.
Source: International Journal of Cardiology - January 21, 2014 Category: Cardiology Authors: Claudia Stöllberger, Birke Schneider, Josef Finsterer Tags: Online Letters to the Editor Source Type: research

Abstract 336: Real-World Experiences with Novel Anticoagulants for AF: Initial Insights from ORBIT-AF Phase II Session Title: Poster Session III
Conclusions: Patients with new-onset AF are frequently treated with novel anticoagulants and these patients have lower risk scores than those with known AF transitioned to a novel drug. These data will provide insights into clinical management and patient centered outcomes among those treated with novel anticoagulants in real world practice settings.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Steinberg, B. A., Milford-Beland, S., Ollis, D., Blanco, R., Ansell, J., Fonarow, G. C., Gersh, B., Go, A., Hylek, E., Kowey, P. R., Mahaffey, K. W., Thomas, L., Chang, P., Peterson, E. D., Piccini, J. P. Tags: Session Title: Poster Session III Source Type: research

New oral anticoagulants in the prevention of thromboembolic complications in atrial fibrillation - a single-center experience.
Abstract Introduction:The prevention of thromboembolic complications in patients with atrial fibrillation(AF) takes priority in this group. In light of applicable guidelines, thesignificance of vitamin K antagonists (VKA) in stroke prevention decreased in favorofan ever more important role of new oral anticoagulants (nOAC). Theobjectives of this study are: theevaluation of the frequency of nOAC recommendations, the comparison between thepopulation of patients treatedwith VKA and those receiving nOAC, as well as theidentification of factors predisposing to the administration of nOAC to AF patients ondischarge.Metho...
Source: Polish Heart Journal - September 2, 2014 Category: Cardiology Authors: Gorczyca-Michta I, Wożakowska-Kapłon B Tags: Kardiol Pol Source Type: research

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
As atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events, most AF patients require appropriate antithrombotic prophylaxis. Oral anticoagulation (OAC) with either dose-adjusted vitamin K antagonists (VKAs) (eg, warfarin) or non-VKA oral anticoagulants (eg, dabigatran, apixaban, rivaroxaban) can be used for this purpose unless contraindicated. Therefore, risk assessment of stroke and bleeding is an obligatory part of AF management, and risk has to be weighed individually. Antiplatelet drugs (eg, aspirin and clopidogrel) are inferior to OAC, both alone and in combination, with a c...
Source: Cardiology Clinics - September 4, 2014 Category: Cardiology Authors: Mikhail S. Dzeshka, Gregory Y.H. Lip Source Type: research

Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation.
CONCLUSIONS: -In general practice settings, dabigatran was associated with reduced risk of ischemic stroke, intracranial hemorrhage, and death, and increased risk of major gastrointestinal hemorrhage compared with warfarin in elderly patients with non-valvular AF. These associations were most pronounced in patients treated with dabigatran 150 mg twice daily, whereas the association of 75 mg twice daily with study outcomes was indistinguishable from warfarin except for a lower risk of intracranial hemorrhage with dabigatran. PMID: 25359164 [PubMed - as supplied by publisher]
Source: Circulation - October 30, 2014 Category: Cardiology Authors: Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA Tags: Circulation Source Type: research

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
As atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events, most AF patients require appropriate antithrombotic prophylaxis. Oral anticoagulation (OAC) with either dose-adjusted vitamin K antagonists (VKAs) (eg, warfarin) or non-VKA oral anticoagulants (eg, dabigatran, apixaban, rivaroxaban) can be used for this purpose unless contraindicated. Therefore, risk assessment of stroke and bleeding is an obligatory part of AF management, and risk has to be weighed individually. Antiplatelet drugs (eg, aspirin and clopidogrel) are inferior to OAC, both alone and in combination, with a c...
Source: Cardiology Clinics - September 1, 2014 Category: Cardiology Authors: Mikhail S. Dzeshka, Gregory Y.H. Lip Source Type: research

Antiplatelet Properties of Oral Anticoagulants
Until recently, vitamin K antagonists (VKA) were the only oral anticoagulant drugs used in clinical practice for stroke or systemic embolism prevention in patients with non-valvular atrial fibrillation (AF). New oral anticoagulant drugs such as dabigatran etexilate and rivaroxaban have been developed and are currently available as an alternative in this indication. Both drugs were demonstrated to be non-inferior to warfarin for the prevention of stroke or systemic embolism in patients with non-valvular AF in the RE-LY and ROCKET trials [1,2].
Source: International Journal of Cardiology - December 23, 2014 Category: Cardiology Authors: Corinne Frère, Marc Laine, Franck Paganelli, Françoise Dignat-George, Laurent Bonello Tags: Letter to the Editor Source Type: research

FDA Approves Edoxaban for Stroke Prevention, DVT/PEFDA Approves Edoxaban for Stroke Prevention, DVT/PE
Edoxaban joins rivaroxaban, apixaban, and dabigatran as the fourth novel oral anticoagulant on the US market, but it does carry a boxed warning of limited efficacy in patients with creatinine clearances greater than 95 mL/min. FDA Approvals
Source: Medscape Cardiology Headlines - January 9, 2015 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis.
CONCLUSIONS: -More dialysis patients are being started on dabigatran and rivaroxaban, even when their use is contraindicated and there are no studies to support the benefits outweigh the risks of these drugs in ESRD. PMID: 25595139 [PubMed - as supplied by publisher]
Source: Circulation - January 16, 2015 Category: Cardiology Authors: Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW Tags: Circulation Source Type: research

Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis
Conclusions This systematic review and meta-analysis suggests that NOACs may be as safe as VKAs in the setting of AF cardioversion.
Source: Clinical Research in Cardiology - February 3, 2015 Category: Cardiology Source Type: research

Clinical Significance of Non-Vitamin K Antagonist Oral Anticoagulants in the Management of Atrial Fibrillation.
Abstract Atrial fibrillation (AF) is the most commonly observed rhythm disorder in clinical practice. It is associated with a high risk of thromboembolic stroke and increased cardiovascular mortality. Vitamin K antagonists (VKAs), the only oral anticoagulants used for thromboembolic prophylaxis in AF patients over the past 60 years, have been effective in reducing thromboembolic stroke, compared with placebo and aspirin, in this group of patients. However, VKAs have a very narrow therapeutic window, so regular monitoring of the therapeutic effect is obligatory for their use. The need for regular assessment of bloo...
Source: Circulation Journal - April 2, 2015 Category: Cardiology Authors: Santarpia G, Curcio A, Sibilio G, Indolfi C Tags: Circ J Source Type: research

Close the appendage, open the future
Left atrial appendage closure is a proven method for prevention against stroke in patients with non-valvular atrial fibrillation. This method is proven for having clinical utility as well as safety. The need for coverage in this area is immense. Atrial fibrillation affects 1%–2% of the entire adult population.1 Of all ischaemic strokes, 15% are associated with atrial fibrillation. Both the CHADS2 and the CHA2DS2-VASc risk scores have been used for determining the level of anticoagulation in these patients. Multiple anticoagulants have been used for prevention of ischaemic stroke, including warfarin, dabigatran, rivar...
Source: Heart - May 12, 2015 Category: Cardiology Authors: Gafoor, S., Sievert, H., Matic, P. Tags: Drugs: cardiovascular system, Epidemiology Editorials Source Type: research

Abstract 157: An Early Assessment of Hospital Readmissions Among Nonvalvular Atrial Fibrillation Treated with the New Oral Anticoagulants, Apixaban, Dabigatran, and Rivaroxaban Session Title: Poster Session I
Conclusion: In this early assessment, treatment with rivaroxaban vs. apixaban was associated with greater risk of all-cause or bleeding-related 1-month readmissions and higher hospital costs due to readmissions.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Deitelzweig, S., Bruno, A., Trocio, J., Tate, N., Lin, J., Lingohr-Smith, M. Tags: Session Title: Poster Session I Source Type: research